This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
It's called targeted radiopharmaceutical therapy. RBC Capital Markets sees a $25 billion market opportunity for the space. "We believe TRT development is still in its early ...
CNBC
7 小時前